ZyVersa Therapeutics, Inc.
ZVSA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001859007
No open-market purchases or sales by ZyVersa Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding ZyVersa Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 6 | 11 | +5 |
| Shares | 141.7K | 297.1K | +155.4K (+109.6%) |
| Value | $273.5K | $73.4K | −$200.1K (−73.2%) |
New holders (7)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 120,377 | $30.0K | 0.00% |
| Cowen and Company, LLC | 50,000 | $12.3K | 0.00% |
| Two Sigma Securities, LLC | 39,498 | $9.70K | 0.00% |
| Cubist Systematic Strategies, LLC | 36,870 | $9.05K | 0.00% |
| StoneX Group Inc. | 12,700 | $3.12K | 0.00% |
| Barclays PLC | 1,100 | $270 | 0.00% |
| Bank of America Corp | 100 | $24 | 0.00% |
Sold out (2)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Goldman Sachs Group Inc | 103,471 | $199.7K |
| UBS Group AG | 3,282 | $6.33K |